Published in J Biol Chem on May 28, 2010
Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov (2011) 1.71
Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils. Nat Chem Biol (2011) 1.54
Characteristics of amyloid-related oligomers revealed by crystal structures of macrocyclic β-sheet mimics. J Am Chem Soc (2011) 1.27
Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity. J Biol Chem (2012) 1.26
Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J Am Chem Soc (2011) 1.25
Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways. J Biol Chem (2010) 1.20
Site specific interaction of the polyphenol EGCG with the SEVI amyloid precursor peptide PAP(248-286). J Phys Chem B (2012) 1.14
Structure-based design of conformation- and sequence-specific antibodies against amyloid β. Proc Natl Acad Sci U S A (2011) 1.05
Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry. Nat Chem (2014) 1.05
Comparison of three amyloid assembly inhibitors: the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01. ACS Chem Neurosci (2012) 1.04
Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem (2013) 1.01
Ligand binding to distinct states diverts aggregation of an amyloid-forming protein. Nat Chem Biol (2011) 1.01
Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. Age (Dordr) (2012) 0.96
Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (aβ) self-assembly. ACS Chem Neurosci (2012) 0.96
A safe, blood-brain barrier permeable triphenylmethane dye inhibits amyloid-β neurotoxicity by generating nontoxic aggregates. ACS Chem Neurosci (2011) 0.95
Natural compounds may open new routes to treatment of amyloid diseases. Neurotherapeutics (2013) 0.92
Structural basis for Aβ1–42 toxicity inhibition by Aβ C-terminal fragments: discrete molecular dynamics study. J Mol Biol (2011) 0.91
Amyloid-β Receptors: The Good, the Bad, and the Prion Protein. J Biol Chem (2015) 0.86
Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid β. Chembiochem (2011) 0.86
Resveratrol inhibits the formation of multiple-layered β-sheet oligomers of the human islet amyloid polypeptide segment 22-27. Biophys J (2011) 0.85
Discovery and structure activity relationship of small molecule inhibitors of toxic β-amyloid-42 fibril formation. J Biol Chem (2012) 0.85
Aggregation modulators interfere with membrane interactions of β2-microglobulin fibrils. Biophys J (2013) 0.85
Suppression of amyloid beta A11 antibody immunoreactivity by vitamin C: possible role of heparan sulfate oligosaccharides derived from glypican-1 by ascorbate-induced, nitric oxide (NO)-catalyzed degradation. J Biol Chem (2011) 0.85
Keampferol-3-O-rhamnoside abrogates amyloid beta toxicity by modulating monomers and remodeling oligomers and fibrils to non-toxic aggregates. J Biomed Sci (2012) 0.84
Mutational analysis of the ability of resveratrol to inhibit amyloid formation by islet amyloid polypeptide: critical evaluation of the importance of aromatic-inhibitor and histidine-inhibitor interactions. Biochemistry (2015) 0.84
Characterization of the oligomerization and aggregation of human Serum Amyloid A. PLoS One (2013) 0.84
Isolating toxic insulin amyloid reactive species that lack β-sheets and have wide pH stability. Biophys J (2011) 0.83
Countering amyloid polymorphism and drug resistance with minimal drug cocktails. Prion (2010) 0.83
Protein folding and aggregation into amyloid: the interference by natural phenolic compounds. Int J Mol Sci (2013) 0.81
Stabilizing Off-pathway Oligomers by Polyphenol Nanoassemblies for IAPP Aggregation Inhibition. Sci Rep (2016) 0.81
Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against Aβ and Aβ-metal complexes toxicity. PLoS One (2011) 0.80
Fine mapping of the amyloid β-protein binding site on myelin basic protein. Biochemistry (2013) 0.80
Brazilin inhibits amyloid β-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity. Sci Rep (2015) 0.80
General amyloid inhibitors? A critical examination of the inhibition of IAPP amyloid formation by inositol stereoisomers. PLoS One (2014) 0.79
Resveratrol as a therapeutic agent for Alzheimer's disease. Biomed Res Int (2014) 0.79
Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell Mol Neurobiol (2013) 0.79
High-resolution NMR characterization of low abundance oligomers of amyloid-β without purification. Sci Rep (2015) 0.79
Prions, proteinase K and infectivity. Prion (2012) 0.78
Caloric restriction: beneficial effects on brain aging and Alzheimer's disease. Mamm Genome (2016) 0.78
Xanthene food dye, as a modulator of Alzheimer's disease amyloid-beta peptide aggregation and the associated impaired neuronal cell function. PLoS One (2011) 0.78
Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal Compounds. Oxid Med Cell Longev (2015) 0.77
Monitoring insulin aggregation via capillary electrophoresis. Int J Mol Sci (2011) 0.77
Halogenation generates effective modulators of amyloid-Beta aggregation and neurotoxicity. PLoS One (2013) 0.77
The Luminescent Oligothiophene p-FTAA Converts Toxic Aβ1-42 Species into Nontoxic Amyloid Fibers with Altered Properties. J Biol Chem (2016) 0.76
Natural biomolecules and protein aggregation: emerging strategies against amyloidogenesis. Int J Mol Sci (2012) 0.76
Techniques for Monitoring Protein Misfolding and Aggregation in Vitro and in Living Cells. Korean J Chem Eng (2012) 0.76
ESI-IMS-MS: A method for rapid analysis of protein aggregation and its inhibition by small molecules. Methods (2015) 0.75
Looking for a generic inhibitor of amyloid-like fibril formation among flavone derivatives. PeerJ (2015) 0.75
Resveratrol and Alzheimer's Disease: Mechanistic Insights. Mol Neurobiol (2016) 0.75
Prions. Proc Natl Acad Sci U S A (1998) 27.80
Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem (2006) 22.87
Resveratrol improves health and survival of mice on a high-calorie diet. Nature (2006) 20.91
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature (2003) 17.52
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov (2006) 11.77
Molecular biology of prion diseases. Science (1991) 10.83
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature (2007) 10.21
Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell (1993) 10.15
A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A (2002) 9.55
Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med (1998) 9.01
Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science (2005) 8.86
3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A (2005) 8.60
Molecular pathways of neurodegeneration in Parkinson's disease. Science (2003) 7.55
Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science (2000) 6.16
Conformational variations in an infectious protein determine prion strain differences. Nature (2004) 6.15
Opposing activities protect against age-onset proteotoxicity. Science (2006) 5.85
Folding proteins in fatal ways. Nature (2003) 5.58
EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol (2008) 5.32
The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol (1998) 5.20
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem (2004) 5.14
Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J Virol (1994) 5.12
Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc Natl Acad Sci U S A (2008) 4.84
Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol (2000) 4.76
Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature (1995) 4.22
Structural classification of toxic amyloid oligomers. J Biol Chem (2008) 4.16
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener (2007) 4.15
Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J Virol (1992) 4.02
Mechanism of prion propagation: amyloid growth occurs by monomer addition. PLoS Biol (2004) 3.75
Alzheimer's disease: genotypes, phenotypes, and treatments. Science (1997) 3.72
Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci U S A (2002) 3.56
The disease characteristics of different strains of scrapie in Sinc congenic mouse lines: implications for the nature of the agent and host control of pathogenesis. J Gen Virol (1991) 3.47
Mammalian prion biology: one century of evolving concepts. Cell (2004) 3.46
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem (2007) 3.42
Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. Proc Natl Acad Sci U S A (2005) 3.37
Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem (2002) 3.37
A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J (2002) 3.34
Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A (2009) 3.06
Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell (2009) 2.87
Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem (2001) 2.77
Transmission of bovine spongiform encephalopathy and scrapie to mice: strain variation and the species barrier. Philos Trans R Soc Lond B Biol Sci (1994) 2.76
Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struct Biol (2007) 2.75
Huntingtin aggregation and toxicity in Huntington's disease. Lancet (2003) 2.72
Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci U S A (2002) 2.62
Prion recognition elements govern nucleation, strain specificity and species barriers. Nature (2007) 2.57
Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters. J Gen Virol (1992) 2.55
EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A (2010) 2.48
A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol (2010) 2.48
Conformational diversity in a yeast prion dictates its seeding specificity. Nature (2001) 2.44
Alzheimer's disease. N Engl J Med (1986) 2.37
Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem (2008) 2.34
Investigation of alpha-synuclein fibril structure by site-directed spin labeling. J Biol Chem (2007) 2.30
Multiple assembly pathways underlie amyloid-beta fibril polymorphisms. J Mol Biol (2005) 2.14
Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem (2004) 2.11
Fluorescence correlation spectroscopy shows that monomeric polyglutamine molecules form collapsed structures in aqueous solutions. Proc Natl Acad Sci U S A (2006) 2.00
Polymorphic fibril formation by residues 10-40 of the Alzheimer's beta-amyloid peptide. Biophys J (2006) 1.84
Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci (2008) 1.75
Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol (2006) 1.72
Kinetics and thermodynamics of amyloid fibril assembly. Acc Chem Res (2006) 1.71
Fibrils with parallel in-register structure constitute a major class of amyloid fibrils: molecular insights from electron paramagnetic resonance spectroscopy. Q Rev Biophys (2008) 1.67
Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem (2003) 1.64
Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry (2004) 1.60
polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction. Proc Natl Acad Sci U S A (2005) 1.57
Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. J Biol Chem (2009) 1.53
Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc Natl Acad Sci U S A (2004) 1.53
A comparison of some biological characteristics of the mouse-passaged scrapie agents, 22A and ME7. Genet Res (1969) 1.45
Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. Biochemistry (1999) 1.45
Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry (2007) 1.44
Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des (2007) 1.36
Generation of prion transmission barriers by mutational control of amyloid conformations. Nature (2003) 1.36
Propagation of prion strains through specific conformers of the prion protein. J Virol (1997) 1.35
Modification of a strain of mouse-adapted scrapie by passage through rats. Res Vet Sci (1968) 1.22
Evidence for a mechanism of amyloid formation involving molecular reorganisation within native-like precursor aggregates. J Mol Biol (2005) 1.19
Seeding-dependent propagation and maturation of amyloid fibril conformation. J Mol Biol (2005) 1.15
Development of tau aggregation inhibitors for Alzheimer's disease. Angew Chem Int Ed Engl (2009) 1.13
Filaments of the Ure2p prion protein have a cross-beta core structure. J Struct Biol (2005) 1.09
Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology (2009) 1.09
Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem (2007) 1.08
Direct and selective elimination of specific prions and amyloids by 4,5-dianilinophthalimide and analogs. Proc Natl Acad Sci U S A (2008) 1.06
Amyloid nucleation and hierarchical assembly of Ure2p fibrils. Role of asparagine/glutamine repeat and nonrepeat regions of the prion domains. J Biol Chem (2003) 1.06
Characterization of the nucleation barriers for protein aggregation and amyloid formation. HFSP J (2007) 1.04
Molecules that target beta-amyloid. ChemMedChem (2007) 1.02
Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro. Bioorg Med Chem (2006) 1.02
Model discrimination and mechanistic interpretation of kinetic data in protein aggregation studies. Biophys J (2009) 1.02
(-)-epigallocatechin-3-gallate (EGCG) maintains kappa-casein in its pre-fibrillar state without redirecting its aggregation pathway. J Mol Biol (2009) 1.01
Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation. Curr Pharm Des (2006) 1.01
Characterization of the formation of amyloid protofibrils from barstar by mapping residue-specific fluorescence dynamics. J Mol Biol (2006) 1.00
Amyloid protofibrils of lysozyme nucleate and grow via oligomer fusion. Biophys J (2009) 1.00
Mechanism of formation of amyloid protofibrils of barstar from soluble oligomers: evidence for multiple steps and lateral association coupled to conformational conversion. J Mol Biol (2007) 0.95
Spin labeling analysis of amyloids and other protein aggregates. Methods Enzymol (2006) 0.95
The native-like conformation of Ure2p in fibrils assembled under physiologically relevant conditions switches to an amyloid-like conformation upon heat-treatment of the fibrils. J Struct Biol (2003) 0.92
The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. J Alzheimers Dis (2009) 0.92
Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of alpha-synuclein. Biochemistry (2004) 0.91
Molecular aspects of Huntington's disease. J Neurosci Res (1998) 0.90
Fluorescence microscopy studies on islet amyloid polypeptide fibrillation at heterogeneous and cellular membrane interfaces and its inhibition by resveratrol. FEBS Lett (2009) 0.88
Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain. Parkinsonism Relat Disord (2001) 0.85
Dequalinium-induced protofibril formation of alpha-synuclein. J Biol Chem (2005) 0.78
Radio-wave heating of iron oxide nanoparticles can regulate plasma glucose in mice. Science (2012) 2.14
Three-dimensional cellular microarray for high-throughput toxicology assays. Proc Natl Acad Sci U S A (2007) 2.09
Silica nanoparticle size influences the structure and enzymatic activity of adsorbed lysozyme. Langmuir (2004) 1.86
E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol Bioeng (2010) 1.65
High-throughput cellular microarray platforms: applications in drug discovery, toxicology and stem cell research. Trends Biotechnol (2009) 1.56
Structure and function of enzymes adsorbed onto single-walled carbon nanotubes. Langmuir (2004) 1.52
Inhibition of NADPH oxidase activation in endothelial cells by ortho-methoxy-substituted catechols. Endothelium (2002) 1.46
Ionic liquid-mediated selective extraction of lignin from wood leading to enhanced enzymatic cellulose hydrolysis. Biotechnol Bioeng (2009) 1.46
Control of the heparosan N-deacetylation leads to an improved bioengineered heparin. Appl Microbiol Biotechnol (2011) 1.33
Room temperature ionic liquids as emerging solvents for the pretreatment of lignocellulosic biomass. Biotechnol Bioeng (2011) 1.31
Analysis of E. coli K5 capsular polysaccharide heparosan. Anal Bioanal Chem (2010) 1.30
Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis. Anal Biochem (2011) 1.28
Unfolding of ribonuclease A on silica nanoparticle surfaces. Nano Lett (2007) 1.26
Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity. J Biol Chem (2012) 1.26
Identification of a novel class in the alpha/beta hydrolase fold superfamily: the N-myc differentiation-related proteins. Proteins (2002) 1.25
Three-dimensional cell culture microarray for high-throughput studies of stem cell fate. Biotechnol Bioeng (2010) 1.22
Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways. J Biol Chem (2010) 1.20
Enzyme activation for organic solvents made easy. Trends Biotechnol (2007) 1.19
Engineering of routes to heparin and related polysaccharides. Appl Microbiol Biotechnol (2011) 1.19
Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. Protein Eng Des Sel (2012) 1.18
Protein-assisted solubilization of single-walled carbon nanotubes. Langmuir (2006) 1.14
Metabolizing enzyme toxicology assay chip (MetaChip) for high-throughput microscale toxicity analyses. Proc Natl Acad Sci U S A (2005) 1.13
Osmolyte trimethylamine-N-oxide does not affect the strength of hydrophobic interactions: origin of osmolyte compatibility. Biophys J (2005) 1.13
Recent progress and applications in glycosaminoglycan and heparin research. Curr Opin Chem Biol (2009) 1.10
Effect of gold nanoparticle morphology on adsorbed protein structure and function. Biomaterials (2011) 1.08
Enzyme activation for nonaqueous media. Curr Opin Biotechnol (2002) 1.08
Spaceflight promotes biofilm formation by Pseudomonas aeruginosa. PLoS One (2013) 1.08
Structural characterization of heparins from different commercial sources. Anal Bioanal Chem (2011) 1.07
On-chip, cell-based microarray immunofluorescence assay for high-throughput analysis of target proteins. Anal Chem (2008) 1.06
Engineering aggregation-resistant antibodies. Annu Rev Chem Biomol Eng (2012) 1.06
Structure-based design of conformation- and sequence-specific antibodies against amyloid β. Proc Natl Acad Sci U S A (2011) 1.05
Toward an artificial Golgi: redesigning the biological activities of heparan sulfate on a digital microfluidic chip. J Am Chem Soc (2009) 1.04
Glycosaminoglycans in infectious disease. Biol Rev Camb Philos Soc (2013) 1.04
Quantitative exploration of the occurrence of lateral gene transfer by using nitrogen fixation genes as a case study. Proc Natl Acad Sci U S A (2006) 1.04
Hydration of enzyme in nonaqueous media is consistent with solvent dependence of its activity. Biophys J (2004) 1.02
Enzymatic synthesis of dextran-containing hydrogels. Biomaterials (2002) 1.01
Structure, function, and stability of enzymes covalently attached to single-walled carbon nanotubes. Langmuir (2007) 1.01
Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions. Proteins (2011) 1.00
Enzymatic synthesis of glycosaminoglycan heparin. Semin Thromb Hemost (2007) 1.00
Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm (2013) 0.99
Nanoparticle-mediated cytoplasmic delivery of proteins to target cellular machinery. ACS Nano (2010) 0.98
The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases. Curr Vasc Pharmacol (2008) 0.98
Escherichia coli K5 heparosan fermentation and improvement by genetic engineering. Bioeng Bugs (2011) 0.97
Substrate profile analysis and ACP-mediated acyl transfer in Streptomyces coelicolor Type III polyketide synthases. Chembiochem (2007) 0.95
Influence of a three-dimensional, microarray environment on human cell culture in drug screening systems. Biomaterials (2012) 0.95
Rational design of potent domain antibody inhibitors of amyloid fibril assembly. Proc Natl Acad Sci U S A (2012) 0.94
Toward aggregation-resistant antibodies by design. Trends Biotechnol (2013) 0.94
Facile pretreatment of lignocellulosic biomass at high loadings in room temperature ionic liquids. Biotechnol Bioeng (2011) 0.93
High cell density cultivation of a recombinant E. coli strain expressing a key enzyme in bioengineered heparin production. Appl Microbiol Biotechnol (2013) 0.93
Cytochrome C on silica nanoparticles: influence of nanoparticle size on protein structure, stability, and activity. Small (2009) 0.93
Gene delivery in three-dimensional cell cultures by superparamagnetic nanoparticles. ACS Nano (2010) 0.93
High-throughput human metabolism and toxicity analysis. Curr Opin Biotechnol (2006) 0.93
The protein-nanomaterial interface. Curr Opin Biotechnol (2006) 0.93
Conductive cable fibers with insulating surface prepared by coaxial electrospinning of multiwalled nanotubes and cellulose. Biomacromolecules (2010) 0.92
Increasing protein stability through control of the nanoscale environment. Langmuir (2006) 0.92
Modulation of curli assembly and pellicle biofilm formation by chemical and protein chaperones. Chem Biol (2013) 0.92
High-throughput, microarray-based synthesis of natural product analogues via in vitro metabolic pathway construction. ACS Chem Biol (2007) 0.92
Dynamic interplay of flow and collagen stabilizes primary hepatocytes culture in a microfluidic platform. Lab Chip (2014) 0.91
Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold. Protein Eng Des Sel (2014) 0.91
Mechanisms of transthyretin inhibition of β-amyloid aggregation in vitro. J Neurosci (2013) 0.91
Water-soluble carbon nanotube-enzyme conjugates as functional biocatalytic formulations. Biotechnol Bioeng (2006) 0.91
Directed assembly of carbon nanotubes at liquid-liquid interfaces: nanoscale conveyors for interfacial biocatalysis. J Am Chem Soc (2006) 0.91
Biocatalytic synthesis of highly ordered degradable dextran-based hydrogels. Biomaterials (2005) 0.91
Enhanced stability of enzymes adsorbed onto nanoparticles. J Nanosci Nanotechnol (2007) 0.90
Active-site motions and polarity enhance catalytic turnover of hydrated subtilisin dissolved in organic solvents. J Am Chem Soc (2009) 0.90
Response surface optimization of the heparosan N-deacetylation in producing bioengineered heparin. J Biotechnol (2011) 0.90
A novel ultrathin collagen nanolayer assembly for 3-D microtissue engineering: Layer-by-layer collagen deposition for long-term stable microfluidic hepatocyte culture. Technology (Singap World Sci) (2014) 0.90
Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions. J Pharm Sci (2014) 0.89
Highly active and stable DNAzyme-carbon nanotube hybrids. J Am Chem Soc (2005) 0.89
Recent advances in sulfotransferase enzyme activity assays. Anal Bioanal Chem (2012) 0.89
How interfaces affect hydrophobically driven polymer folding. J Phys Chem B (2009) 0.89
Plasmonic measurements of monoclonal antibody self-association using self-interaction nanoparticle spectroscopy. Biotechnol Bioeng (2014) 0.89
High-throughput analysis of concentration-dependent antibody self-association. Biophys J (2011) 0.89
Biocompatibility of chemoenzymatically derived dextran-acrylate hydrogels. J Biomed Mater Res A (2004) 0.89
Inhibition of human vascular NADPH oxidase by apocynin derived oligophenols. Bioorg Med Chem (2009) 0.89
Comparative void-volume analysis of psychrophilic and mesophilic enzymes: Structural bioinformatics of psychrophilic enzymes reveals sources of core flexibility. BMC Struct Biol (2011) 0.88
Combinatorial formulation of biocatalyst preparations for increased activity in organic solvents: salt activation of penicillin amidase. Biotechnol Bioeng (2004) 0.88
Nanotube-assisted protein deactivation. Nat Nanotechnol (2007) 0.88
Enzymatically derived sugar-containing self-assembled organogels with nanostructured morphologies. Angew Chem Int Ed Engl (2006) 0.88
Exposure to carbon nanotubes leads to changes in the cellular biomechanics. Adv Healthc Mater (2013) 0.87
High-throughput screening and quantitative structure-efficacy relationship models of potential displacer molecules for ion-exchange systems. Biotechnol Bioeng (2002) 0.87
Tubulin encapsulation of carbon nanotubes into functional hybrid assemblies. Small (2009) 0.87
Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid β. Chembiochem (2011) 0.86
Apocynin derivatives interrupt intracellular signaling resulting in decreased migration in breast cancer cells. J Biomed Biotechnol (2006) 0.86
Analysis of glycosaminoglycans in stem cell glycomics. Methods Mol Biol (2011) 0.86
Water dynamics and salt-activation of enzymes in organic media: mechanistic implications revealed by NMR spectroscopy. Proc Natl Acad Sci U S A (2006) 0.86
Silica-immobilized enzymes for multi-step synthesis in microfluidic devices. Biotechnol Bioeng (2007) 0.86